<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057351</url>
  </required_header>
  <id_info>
    <org_study_id>H.E.HU.AD.NSO05.066.05.00</org_study_id>
    <nct_id>NCT05057351</nct_id>
  </id_info>
  <brief_title>A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis</brief_title>
  <official_title>Randomized, Double Blind, Clinical Study for Evaluating the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis. Controlled Study vs Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Greenpharma S.A.S.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Complife Italia S.r.l</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Greenpharma S.A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety and clinical efficacy of an active ingredient versus placebo for the&#xD;
      treatment of mild to moderate Atopic Dermatitis (AD) adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single center, randomized, double-blind, placebo-controlled, parallel group study, carried on 2 groups of 22 subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in severity of Atopic Dermatitis as assessed using the SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>7, 14 and 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Mild to Moderate Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Active ingredient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isopentenyltheophylline 0.44% + Glycerin 4.56%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glycerin 4.56%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isopentenyltheophylline 0.44% + Glycerin 4.56%</intervention_name>
    <description>Application of topical cream twice a day on the area affected by Atopic Dermatitis</description>
    <arm_group_label>Active ingredient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glycerin 4.56%</intervention_name>
    <description>Application of topical cream twice a day on the area affected by Atopic Dermatitis</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  Phototype I to IV&#xD;
&#xD;
          -  Mild to moderate SCORAD (between 15 and 25)&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant/breastfeeding female or who have planned a pregnancy during the study period&#xD;
&#xD;
          -  Positive history for atopy or hypersensitive skin&#xD;
&#xD;
          -  Subjects under systemically pharmacological treatment&#xD;
&#xD;
          -  Subjects under locally pharmacological treatment on the skin area monitored during the&#xD;
             test&#xD;
&#xD;
          -  Subjects with congenital or acquired immunodeficiency&#xD;
&#xD;
          -  Subjects under treatment with food supplements which could interfere with the&#xD;
             functionality of the product under study&#xD;
&#xD;
          -  Subjects which show other skin alterations on the monitored area except for acne&#xD;
             lesions&#xD;
&#xD;
          -  Subjects with known or suspected sensitization to one or more test formulation&#xD;
             ingredients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Roveda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complife Italia S.r.l</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complife Italia S.r.l.</name>
      <address>
        <city>San Martino Siccomario</city>
        <zip>27028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

